Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405877 | 0.94 | — | — | |
| SCHEMBL5613588 | 0.79 | PTGS2 (0.35) | LMNACYP3A4MAPTTDP1 | |
| SCHEMBL7648194 | 0.78 | SKP2 (0.31) | — | |
| SCHEMBL4663340 | 0.78 | SKP2 (0.31) | — | |
| SCHEMBL3752202 | 0.78 | HRH1 (0.34) | LMNA | |
| SCHEMBL13049891 | 0.73 | LMNA (0.42) | LMNAPGRCYP3A4CYP2D6MAPT | |
| SCHEMBL4197781 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL20583808 | 0.72 | NOS3 (0.34) | — | |
| SCHEMBL3757885 | 0.71 | FAAH (0.40) | LMNAPGRCYP3A4MAPTCYP2C9 | |
| SCHEMBL20583809 | 0.71 | CHRM1 (0.35) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865924-B2 | Compounds for use as ligands | UNIVERSITY OF LEEDS (GB) | 2014-10-21 | — | — | US | claimed |
| US-20130267725-A1 | COMPOUNDS FOR USE AS LIGANDS | UNIVERSITY OF LEEDS (GB) | 2013-10-10 | — | — | US | claimed |
| US-8501829-B2 | Compounds for use as ligands | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2013-08-06 | — | — | US | claimed |
| US-20100298457-A1 | COMPOUNDS FOR USE AS LIGANDS | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2010-11-25 | — | — | US | claimed |
| EP-2252622-A2 | COMPOUNDS FOR USE AS LIGANDS | NPIL Pharmaceuticals (UK) Limited (GB) | 2010-11-24 | — | — | EP | claimed |
| WO-2009093059-A2 | COMPOUNDS FOR USE AS LIGANDS | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-07-30 | — | — | WO | claimed |
| US-9399211-B2 | Microencapsulated catalyst-ligand system | REAXA LIMITED (GB) | 2016-07-26 | — | — | US | disclosed |
| US-20160030935-A1 | MICROENCAPSULATED CATALYST-LIGAND SYSTEM | REAXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| EP-2252622-B1 | COMPOUNDS FOR USE AS LIGANDS | UNIV LEEDS (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-8865924-B2 | Compounds for use as ligands | UNIVERSITY OF LEEDS (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20130267725-A1 | COMPOUNDS FOR USE AS LIGANDS | UNIVERSITY OF LEEDS (GB) | 2013-10-10 | — | — | US | disclosed |
| US-8501829-B2 | Compounds for use as ligands | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20100298457-A1 | COMPOUNDS FOR USE AS LIGANDS | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2252622-A2 | COMPOUNDS FOR USE AS LIGANDS | NPIL Pharmaceuticals (UK) Limited (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090221419-A1 | Microencapsulated Catalyst-Ligand System | REAXA LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| WO-2009093059-A2 | COMPOUNDS FOR USE AS LIGANDS | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298457-A1 | COMPOUNDS FOR USE AS LIGANDS | SELL, SELE, NCL | LMNA 4498/4885PGR 1485/4885CYP3A4 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.